Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Chinese Patent Office
Colorcon
Citi
Deloitte
Cipla
Julphar
Healthtrust

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,871,745

« Back to Dashboard

Which drugs does patent 8,871,745 protect, and when does it expire?

Patent 8,871,745 protects NINLARO and is included in one NDA.

This patent has fifty-four patent family members in thirty-four countries.
Summary for Patent: 8,871,745
Title:Proteasome inhibitors
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/964,708
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery;

Drugs Protected by US Patent 8,871,745

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-001 Nov 20, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,871,745

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,003,819 Proteasome inhibitors ➤ Sign Up
8,530,694 Proteasome inhibitors ➤ Sign Up
7,442,830 Proteasome inhibitors ➤ Sign Up
8,772,536 Proteasome inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Cerilliant
Dow
Covington
Chinese Patent Office
Argus Health
McKesson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.